Sanofi

What Sanofi does

Sanofi India Limited (BSE: 500674, NSE: Sanofi) is a publicly listed pharmaceutical company incorporated in May 1956 as Hoechst Fedco Pharma Private Limited, renamed through successive corporate restructurings (Hoechst Pharmaceuticals, Hoechst India, Hoechst Marion Roussel, Aventis Pharma) to its current name. The company operates across four core therapeutic verticals: diabetes management, rare diseases, transplant medications, and preventive vaccines, distributing products in India through a direct medical representative network targeting hospitals, clinics, and healthcare professionals, while also exporting to developed and developing countries. In June 2024, the consumer healthcare business was demerged into a standalone entity, Sanofi Consumer Healthcare India Ltd, separating OTC brands (Allegra, Combiflam, Dulcoflex) from core pharma operations.

The company employs approximately 3,000 people across India, with its headquarters at Sanofi House in Powai, Mumbai, and a 250,000-square-foot Hyderabad innovation center (House of Dreams) housing 2,000+ employees as part of a Global Capability Centre expansion. In May 2026, Sanofi India launched AccelRare, an AI-driven pre-diagnosis tool that processes structured clinical and symptom data to identify 310 rare disease conditions in children with 88% accuracy; the tool was co-developed with 67 rare disease experts across 13 rare disease networks and has been approved as a Class A medical device in India, distributed free to pediatricians and general physicians.

Sanofi India is majority-controlled by France-based Sanofi and its 100% subsidiary Hoechst GmbH, which together hold 60.4% of paid-up share capital, with the remaining 39.6% publicly traded. FY2025 standalone net sales were Rs 1,837.40 crore (down 8.73% YoY) and net profit was Rs 326.70 crore (down 20.99% YoY); the company declared a final dividend of Rs 48 per share for FY2025 with a record date of April 22, 2026. Institutional activity around the stock includes Nippon India Mutual Fund acquiring an additional 1.14% stake in June 2026.

Name

Sanofi

Legal name

Sanofi India Limited

Website

https://sanofiindialtd.com

Company type

Public

Founded year

1956

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Sanofi India Limited is a publicly listed pharmaceutical company (BSE: 500674) operating across diabetes, rare diseases, transplant, and vaccines, distributing products through medical representatives in India and to export markets while recently launching AccelRare, an AI-driven rare-disease pre-diagnosis tool.

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Cold, Flu & Cough Remedies (HLAIADAB)

akta.pro secondary industries

Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges) (CRADAMAD), Digestive Health OTC (Antacids, Laxatives, Anti-diarrheals, Probiotics OTC) (CRADAMAE)

Keywords

• Pharmaceutical products
• Diabetes therapies
• Rare disease treatments
• Vaccines
• Consumer healthcare

Headquarters

HQ city

Mumbai

HQ country

India

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Marketing or Sales, Personnel, Technology or R&D, Infrastructure

Revenue model

1. Pharmaceutical Products: Sale of pharmaceutical products including diabetes therapies, rare disease treatments, and transplant medications. Products are distributed in India and exported to many developed as well as developing countries.
2. Vaccines: Preventive healthcare through vaccine products offered in India.
3. Consumer Healthcare Products: Consumer healthcare business (demerged into Sanofi Consumer Healthcare India Ltd in June 2024) includes products like Allegra Suspension, Combiflam Suspension, and Dulcoflex. Revenue from Q1 showed Rs 229 crore with 32.8% growth.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Sanofi India Limited manufactures and distributes pharmaceutical therapies (diabetes, rare diseases, transplant), preventive vaccines, and specialty care products across India with parallel exports to developed and developing countries. A demerged consumer healthcare business (Sanofi Consumer Healthcare India Ltd) markets OTC products such as Dulcoflex, Allegra Suspension, and Combiflam Suspension. Sanofi's newest standalone offering is AccelRare, a free AI-driven web-based pre-diagnosis tool for 310 rare diseases, approved as a Class A medical device in India.

Product overview

Sanofi operates in India through Sanofi India Limited, offering a diversified healthcare portfolio comprising pharmaceutical products (including diabetes, rare diseases, and transplant therapies), preventive vaccines, and specialty care products. The company also maintains a consumer healthcare division with over-the-counter products including Dulcoflex (constipation relief), Allegra Suspension (allergy), and Combiflam Suspension (pain relief). Sanofi has recently launched AccelRare, an AI-driven digital health tool for rare disease pre-diagnosis. Products are distributed domestically in India and exported to developed and developing countries. Sanofi employs approximately 3,000 people across India, with its Hyderabad office serving as an innovation center.

Differentiator

Problem solved

Functional benefit

Brands

• AccelRare: AI-driven pre-diagnosis tool that helps medical practitioners identify rare diseases in children, covering 310 conditions with 88% accuracy. Approved as a Class A medical device in India.

Products and services

• Pharmaceutical Products Therapies for diabetes, rare diseases, and transplant needs, distributed in India and exported to developed and developing countries via medical representatives.
• Vaccines Preventive healthcare vaccines provided as part of Sanofi's portfolio in India, delivered through healthcare professional channels.
• Specialty Care Products Specialty care pharmaceutical products targeting specific therapeutic areas including rare diseases, diabetes, and transplant therapies.
• AccelRare Free web-based AI-driven pre-diagnosis tool that helps medical practitioners identify rare diseases in children, covering 310 conditions with 88% accuracy; approved as a Class A medical device in India.
• Lantus SoloStar Insulin product widely prescribed in India for diabetes patients.
• Dulcoflex Constipation relief brand distributed in India as part of the demerged Sanofi Consumer Healthcare India Ltd portfolio.
• Allegra Suspension Anti-allergy medication in suspension form, part of Sanofi Consumer Healthcare India Ltd's portfolio.
• Combiflam Suspension Pain relief suspension combining ibuprofen and paracetamol, part of Sanofi Consumer Healthcare India Ltd's portfolio.

Quantifiable outcome

• 88% accuracy in identifying 310 rare disease conditions
• +4 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature1 record

Partnerships

One partnership is on record.

• 67 rare disease experts across 13 rare disease networkscoreStrategic or Co-development Partner · 26 May 2026Co-development partnership with 67 rare disease experts across 13 rare disease networks to create AccelRare, an AI-driven pre-diagnosis tool covering 310 rare disease conditions with 88% accuracy. Approved as a Class A medical device in India.

Scale indicators13 records

Recent moves3 records

Expansion highlights5 records

Direct peers

• AstraZeneca Pharma India: India-listed subsidiary of AstraZeneca, operating as an MNC pharma with similar specialty/prescription therapeutic categories.
• GlaxoSmithKline Pharmaceuticals India: India-listed subsidiary of global pharma MNC GSK, focused on prescription pharmaceuticals and vaccines with a similar mid-cap listed entity profile in India.
• Novo Nordisk India: Global leader in insulin and diabetes care with a strong India presence, head-to-head with Sanofi India in the diabetes therapy franchise.
• Pfizer India: India arm of global pharma major Pfizer, directly competing with Sanofi India in prescription therapeutics and vaccines.
• Dr. Reddy's Laboratories: India-headquartered global pharmaceutical manufacturer with strong prescription pharma and biosimilar presence, including diabetes and specialty therapeutics.
• Sun Pharmaceutical Industries: India's largest pharmaceutical company by revenue, competing with Sanofi India across specialty and prescription therapies including diabetes and rare-disease adjacencies.
• Abbott India: India-listed subsidiary of Abbott with a comparable mid-cap pharma portfolio and parallel MNC-subsidiary structure.
• Novartis India: India-listed subsidiary of Novartis, a global MNC pharma with overlapping specialty and prescription therapeutic franchises.
• Cipla: Major Indian pharma manufacturer with broad prescription therapeutic coverage, competing for the same prescriber base in respiratory, diabetes and specialty care.

Emerging players

• Biocon: India-listed biopharmaceutical company with insulin, biosimilars and specialty therapeutics that competes with Sanofi India in diabetes and biologics adjacencies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sanofi